Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Pain. 2020 May;161(5):1037–1043. doi: 10.1097/j.pain.0000000000001791

Fig 5.

Fig 5.

A. Examples of CSD traces of the saline, isotype and fremanezumab treated groups showing no differences in the amplitude between them. B. Box plot showing no differences in the amplitude of the CSD wave between the saline treated group and the Isotype (p=0.54) and Fremanezumab (p=0.35) treated groups. (CSD amplitude was 24.7 mV [IQR: 20.1 to 27.4] in the control group (n=24), 24.7 mV [IQR: 20.4 to 29.7] in the isotype group (n=22), and 26.6 mV [IQR: 20.0 to 28.5] in the fremanezumab group (n=20). There was no significant difference between the Fremanezumab and isotype treated groups (p>0.05).